LC
ESPR

Lindbrook Capital’s Esperion Therapeutics ESPR Stock Holding History

Lindbrook Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-255
Closed -$561 – 2826
2024
Q4 		$561 Hold
255
– – ﹤0.01% 2590
2024
Q3 		$421 Buy
+255
New +$515 ﹤0.01% 2709
2023
Q2 		– Sell
-825
Closed -$1.31K – 2760
2023
Q1 		$1.31K Sell
825
-686
-45% -$3.54K ﹤0.01% 2397
2022
Q4 		$9.41K Buy
1,511
+285
+23% +$2.04K ﹤0.01% 1465
2022
Q3 		$8K Sell
1,226
-22
-2% -$151 ﹤0.01% 1415
2022
Q2 		$8K Sell
1,248
-426
-25% -$2.42K ﹤0.01% 1345
2022
Q1 		$8K Buy
+1,674
New +$7.18K ﹤0.01% 1372
2019
Q2 		– Sell
-300
Closed -$12K – 1428
2019
Q1 		$12K Buy
+300
New +$13.5K ﹤0.01% 838

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lindbrook Capital's ESPR Position: Q1 2025 in Review

Lindbrook Capital sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 255 shares — an estimated $561 sold.

Lindbrook Capital first reported a position in ESPR in Q1 2019 and held it in 8 quarters. The position peaked at $12K in Q1 2019. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Lindbrook Capital reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 255 Esperion Therapeutics shares in Q1 2025, an estimated $561.
  • Lindbrook Capital first reported a position in Esperion Therapeutics in Q1 2019 and held it in 8 quarters.
  • Lindbrook Capital's Esperion Therapeutics position peaked at $12K in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.